Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Randomised, Drug Interaction Study of Pyramax (Pyronaridine Artesunate) and the Protease Inhibitor Ritonavir in Healthy Volunteers

NCT01156389 is registered in ClinicalTrials.gov with Medicines for Malaria Venture as lead sponsor.

NCT NCT01156389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01156389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Randomised, Drug Interaction Study of Pyramax (Pyronaridine Artesunate) and the Protease Inhibitor Ritonavir in Healthy Volunteers
Lead sponsor
Medicines for Malaria Venture
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2010
Completion date
September 30, 2010
Enrollment
34 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria